Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]

View source ↗

Summary

Phase I study of CYC140, a PLK-1 inhibitor, in advanced leukemias and myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYC140

Snippet

Sponsor: Cyclacel Pharmaceuticals, Inc. | Conditions: AML, Adult, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED